Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
ConditionBone Metastases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCostantino Errani
About this trial
From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022.
A review will be made from the medical records, radiological imaging, and histological data of these patients
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases
Availability of imaging and clinical data
Availability of at least one follow-up during the last 12 months form diagnosis
Disqualifiers
At least one inclusion creteria not met
Trial population
Male and female adult patients, affected by bone metastases derived from carcinoma, treated at Rizzoli Ortopaedic institute from 01/01/2010 to 31/12/2022.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Analysis
Other interventionAnalysis and review of imaging and clinical data
Treatment groups
250 Participants
are divided into 1 treatment groupGroup A: Patients1 intervention
Trial outcomes
Primary outcomes
1
Creation a dataset of clinical data and diagnostic images
Creation a dataset of clinical data and diagnostic images, called RAW, relating to patients suffering from metastatic bone cancer that will be used by the unit UNICH to create innovative models for fracture risk prediction and of life expectancy based on various patient clinical parameters.
Time frame
At baseline (Day 0)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Costantino Errani
Lead sponsor
Istituto Ortopedico Rizzoli
Sponsor institution
Source ClinicalTrials.gov